House of Commons Hansard #30 of the 43rd Parliament, 1st Session. (The original version is on Parliament's site.) The word of the day was universal.

Topics

Opposition Motion—PharmacareGovernment Orders

12:40 p.m.

Conservative

Tom Kmiec Conservative Calgary Shepard, AB

Madam Speaker, I have been listening to what people have been saying. I have more of a commentary on what the member said and what his colleague said when he introduced the motion this morning.

On November 25, 2019, the minister of finance in Alberta sent a letter to the Minister of Finance federally, indicating that Alberta would not participate in a national pharmacare program. In fact, Alberta would be asking for the same deal that Quebec has. I just want to make that part of the official record here, that it is an official ask from the Alberta government.

In this debate, too few members have talked about access. They have talked about prices and how difficult it is to pay for some of the latest medication and prescription medicine. Access for patients is what patients want to hear about, and too few members have mentioned it. I think the member for Montcalm was the first one to actually make a big deal out of it. For patients with cystic fibrosis and patients with chronic kidney conditions, like my children, national pharmacare is a recipe for disaster.

I look at CADTH. CADTH twice said no to Orkambi. In the patchwork system in the United States, people can get access to Orkambi. They can get access to Trikafta. They can get access to needed medication.

I just want members to be careful. When they say that it would give access to everybody, it would not. This system would not work for rare disease patients.

Opposition Motion—PharmacareGovernment Orders

12:40 p.m.

NDP

Daniel Blaikie NDP Elmwood—Transcona, MB

Madam Speaker, there has been a lot of debate, discussion and research on how medication for rare diseases is a separate category and needs to be treated differently. The idea is not that a national pharmacare plan would be a panacea for every patient and for every condition. The fact of the matter is, as the member has been pointing out often in the House and not just in the debate today, people already have trouble accessing those drugs in Canada under a patchwork system. That is not a reason not to have a system that makes it a lot easier and a lot cheaper to access common drugs for most Canadians, and then work on an appropriate solution for people who are struggling to get access to medication for rare diseases.

The member sees these two things as being in fundamental opposition. I disagree. He is identifying a legitimate need that needs a policy response, but the policy response is not to negate all of the benefits of a national pharmacare plan.

Opposition Motion—PharmacareGovernment Orders

12:45 p.m.

NDP

The Assistant Deputy Speaker NDP Carol Hughes

The member for Berthier—Maskinongé has time for a brief question.

Opposition Motion—PharmacareGovernment Orders

12:45 p.m.

Bloc

Yves Perron Bloc Berthier—Maskinongé, QC

Madam Speaker, I commend my colleague on his intervention.

I would like to ask him about the level of intervention being suggested by the NDP. Why do they fail to understand that health is a jurisdiction of Quebec?

My two colleagues, the hon. members for Montarville and Montcalm, clearly asked the NDP why they omitted from their proposal the fact that Quebec has the right to opt out with full compensation. I heard them say, off mike, that it is in their platform. I am sorry, but to us platforms are vague promises. Canada has made plenty of vague promises. I could spend 45 minutes listing those promises and run out of time. We no longer believe the vague promises.

What was the real purpose of this omission?

I am sorry to have to vote against the motion. We are in favour of pharmacare, but we are here to protect Quebeckers and the National Assembly. We will have to vote against the motion.

What is the real reason the NDP omitted Quebec's right to opt out? Did they want to come across as more progressive than we are?

Opposition Motion—PharmacareGovernment Orders

12:45 p.m.

NDP

The Assistant Deputy Speaker NDP Carol Hughes

I must ask the hon. member for Elmwood—Transcona to answer the question. When I say that we have time for a brief question, that is what I expect.

The hon. member for Elmwood—Transcona.

Opposition Motion—PharmacareGovernment Orders

12:45 p.m.

NDP

Daniel Blaikie NDP Elmwood—Transcona, MB

Madam Speaker, our health critic said today that it is part of our policy and it is in our platform.

We hope to have a program that works. Quebeckers can participate in the program if they wish. We are open to them joining it if they want to. We do not want to begin the process with the assumption that they will not participate. We want to convince them to join it, but we recognize that it is up to them.

Opposition Motion—PharmacareGovernment Orders

12:45 p.m.

NDP

Laurel Collins NDP Victoria, BC

Madam Speaker, first I want to thank my hon. colleague for splitting his time and thank him for his excitement about me speaking. I am honestly in awe of his speech. He spoke eloquently and made it so clear how this is sensible and straightforward.

In Canada, we have a universal health care system and it is a source of pride for many people in our country, especially when we look south at the inequalities in the U.S. private health care system. Everyone should be able to access health care. It is not just for the people who can afford it. Health care is a fundamental human right.

However, Canada, as has been mentioned before, is the only industrialized country with a so-called universal health care system that does not include universal comprehensive public coverage for prescription medications. When it comes to medications, we are actually more similar to the U.S. than we are different. One out of every five Canadians is not taking their medication because they cannot afford it. Many Canadians are cutting their pills in half or even skipping their medication completely. Too many Canadians are ending up in the ER and in hospitals for longer stays because they cannot afford the essential prescriptions that they need. Hundreds have died prematurely every year.

Even people with private drug coverage have been seeing their employer benefits shrink, finding themselves working in more precarious jobs and feeling the squeeze on their family budget. Out of the three million Canadians who cannot afford their medication, 38% of those are on private insurance, but that private insurance does not actually cover enough of their costs and 21% have some form of public insurance that does not fully cover their costs.

Canada's currently fragmented, patchwork system of drug coverage, where each province is offering different levels of coverage with more than 100 public and more than 100,000 private drug insurance plans, is not working for Canadians. This patchwork system is also one of the main reasons why as a country we are consistently paying among the highest prices in the world for prescription drugs. Why is this allowed to occur when it does not make sense for Canadians?

The Liberals have been promising pharmacare for 23 years over and over again, but instead of delivering on that promise to Canadians, they have been helping deliver bigger and bigger profits to pharmaceutical and insurance companies. We recently found out that a so-called national pharmacare working group was sponsored by some of the biggest pharmaceutical and insurance companies in the world. We know that these pharmaceutical companies have been lobbying pretty effectively against single-payer pharmacare. A truly universal pharmacare system is not in the interest of these multinational corporations, but it is in the interest of hard-working Canadians. It is in the interest of small businesses and start-ups.

The federal government's own expert panel found that a universal single-payer system would save businesses over $600 per year, per employee. It would also particularly help small businesses and start-ups currently unable to afford employee drug coverage since it not only removes financial burdens from these businesses, but it also boosts productivity and results in fewer sick days.

It is in the interest of Canadians and small businesses. Health experts say that this is the way to go, but it is not in the interest of big pharmaceutical lobbyists. Who is the government going to listen to? For 23 years, over and over again, each time the Liberals say they are going to look out for Canadians, they turn around and look out for multinational pharmaceutical corporations. Last year, they promised pharmacare again, but they have taken no concrete action to make it happen.

In order to establish universal public pharmacare across Canada, Parliament must pass enabling legislation and the federal government must negotiate transfers with the provinces and territories, yet the Liberal government has remained silent on these foundational steps. Despite campaigning on pharmacare last fall, it has not committed to a truly universal single-payer system as recommended by its own Hoskins report. It also has not provided any timelines for implementation.

People are struggling now and they need action now. A resident of Victoria shared with me that he is on a disability pension and he spends about $100 a month on prescription medication. He knows he should be eating healthier food to complement his medication, but he is struggling to afford both.

This choice is all too common, choosing between essential medication and life's basic necessities. This is a choice that people should never have to make. The government has an opportunity to remedy this. The NDP is introducing this motion and, if passed, if we established a Canadian pharmacare act and provided the first steps in making universal pharmacare a reality, we could address the concerns of this resident and the many Canadians who are struggling to pay for essential medication.

Yesterday, the World Health Organization declared COVID-19 a pandemic. Once implemented, a pharmacare plan would be free for Canadians, it would make emergency wait times shorter, free up hospital beds and save the government $4.2 billion. Countries around the world are facing the possibility of having their health care systems overwhelmed. Now more than ever we need to make sure that ER wait times are shorter and that we have free hospital beds for those who really need them. We need to make sure that Canadians have access to the services that they depend on.

Canadians are struggling to access medication, and they are struggling with affordability of housing, food, dental care and child care. It is hard to make ends meet while everything is getting so expensive. This plan would save Canadians an average of $500 a year, and it would save employers $600 a year or more per insured worker.

I heard from so many of my community members who struggle to afford their medication, and I promised that I would fight for them. I promised that I would fight to take the next big step for our country with a truly universal, public, single-payer pharmacare system.

Like so many, when we are talking about health care and the cost of medication, it feels personal. My dad was diagnosed with terminal cancer just over 10 years ago. At the time, the doctors told him that he had about nine months and that he should be preparing his family. At the time, he joked and said that the downside was that he had cancer so bad that they could not do anything for him. The upside was that he had cancer so bad that they could not do anything for him. Luckily they did. He was put on an experimental clinical trial with an experimental treatment of calcium flushes for the bone cancer, and he is still with us today. He still has cancer, and his medication costs have fluctuated over the years, sometimes totalling $3,000 a month. Thankfully, most of it is covered.

If members could not already tell, my dad has a dark sense of humour, like many cancer survivors. He joked with me a few months ago that, thank God he has terminal cancer so that his medication is covered. However, there is a sad seed of truth in that. Many people in our country are struggling to pay for essential medication. Nobody should have to make the choice between food and medication, between paying for their rent and keeping a roof over their head and paying for their prescriptions. We need a government that is truly committed to universal pharmacare, not one that is trying use a hodgepodge of pharmacare promises, a patchwork system and more empty words to signal to voters that they are still progressive.

Adding medication to our national health care plan cannot be another broken Liberal promise. It cannot be, “Maybe someday we'll get around to it.” This is about life and death, and we need a government that understands that. We need to think boldly again, and we need to do the hard work to continue to build a country that we can be proud of, a Canada where people have access to the services they need when they need them, where nobody is making these impossible choices, and where politicians understand that these issues are personal to so many Canadians.

To me, fighting for that Canada, it is personal. We need courageous action from our elected officials, so I urge each colleague to support the Canadian pharmacare act because it is the right thing to do for constituents. It is my hope—

Opposition Motion—PharmacareGovernment Orders

12:55 p.m.

NDP

The Assistant Deputy Speaker NDP Carol Hughes

The time is up. I did try to allow some more time and signal to the member. I know that this is quite a passionate discussion. Maybe she could add more during questions and comments.

The hon. parliamentary secretary to the government House leader.

Opposition Motion—PharmacareGovernment Orders

12:55 p.m.

Winnipeg North Manitoba

Liberal

Kevin Lamoureux LiberalParliamentary Secretary to the President of the Queen’s Privy Council for Canada and to the Leader of the Government in the House of Commons

Madam Speaker, I listened to my friend's passion on the issue. The government under the leadership of the current Prime Minister has taken significant steps toward a national pharmacare program where people will be able to get prescribed medicines that they so badly need.

I could not help but reflect on another era when we had a Liberal minority government, when there was the Kelowna Accord and a child accord to enhance day care. Because the NDP did not support the Liberals when it came to budget time, the Liberals were defeated and it virtually killed those very important accords.

What would my colleague's advice be to her colleagues if, in fact, we see an incorporation in some fashion for pharmacare continuing to move forward, in regard to the upcoming budget?

Opposition Motion—PharmacareGovernment Orders

12:55 p.m.

NDP

Laurel Collins NDP Victoria, BC

Madam Speaker, rather than advice for my colleagues, I am going to offer some advice to the member and to the Liberal Party as a whole, and that is to follow through on their commitments. It has been 23 years and drug costs just in this Parliament have gone up every single year since the Liberals took office.

Over the same period, the Liberal government has met with big pharma and insurance lobbyists more than 875 times. It is clear who the government is working for and it is not everyday people.

Opposition Motion—PharmacareGovernment Orders

1 p.m.

Conservative

Damien Kurek Conservative Battle River—Crowfoot, AB

Madam Speaker, I appreciate the member's comments and the story she shared about her dad's cancer is a touching one. I know I have similar stories in my family.

I would like to make a brief comment. She mentioned that pharmacare would result in free things for Canadians. The reality is that that is simply not the case. We see ballooning administration costs and bureaucracies that would keep the actual front-line services from getting the resources that they need.

My question for the member is quite simple. I have a number of small business owners, pharmacists, in my constituency who are very concerned about the current status of being able to access the medications that are prescribed to patients today. They are terrified. I use the word “terrified” because that is the word that was shared with me. These are small-town health care providers and pharmacists on the front line. They are terrified that they will not be able to access the drugs because of bloated government bureaucracy that would be the result of a national pharmacare strategy.

Opposition Motion—PharmacareGovernment Orders

1 p.m.

NDP

Laurel Collins NDP Victoria, BC

Madam Speaker, I think that my colleague previously spoke very well about these two different issues, one about access to specific medication for rare diseases, which needs to be addressed, and the other issue around single-payer universal health care. A year's supply of atorvastatin, a widely used cholesterol drug, costs about $143 in Canada but only—

Opposition Motion—PharmacareGovernment Orders

1 p.m.

An hon. member

There is a shortage of that drug.

Opposition Motion—PharmacareGovernment Orders

1 p.m.

NDP

The Assistant Deputy Speaker NDP Carol Hughes

I remind members that if there are other questions and comments, they should wait.

I would ask that the hon. member to continue briefly, so that I can try and allow another question.

Opposition Motion—PharmacareGovernment Orders

1 p.m.

NDP

Laurel Collins NDP Victoria, BC

Madam Speaker, it only costs $27 in the United Kingdom and Sweden, and $15 in New Zealand, so we can see very clearly that this would save Canadians money. If colleagues just read the Hoskins report, they would see that the pharmacare strategy would save small businesses and employers money as well. This is a benefit to Canadians.

Opposition Motion—PharmacareGovernment Orders

1 p.m.

Bloc

Michel Boudrias Bloc Terrebonne, QC

Madam Speaker, obviously, we agree with the substance of the motion. As we have heard, Quebec is setting an example when it comes to protection and coverage for medical care, particularly regarding pharmacare. We already have a system that works, the first in Canada, which serves as a model. We fully agree on that.

However, it is important to keep in mind that this is a provincial jurisdiction and that the federal government spends $300 billion a year. Of that amount, $100 billion goes to real services, while $200 billion in transfer payments of all kinds are used to force the hand of various governments and blackmail them.

Would my colleague not agree that the money should be transferred to the provinces so they can create their own pharmacare programs?

Opposition Motion—PharmacareGovernment Orders

1 p.m.

NDP

Laurel Collins NDP Victoria, BC

Madam Speaker, I share the member's concern for these issues. It is true that Quebec has its own public system. If Quebec wants to, it can continue to have that system and get compensation.

Honestly, Quebeckers are paying so much in drug costs, partially because the federal government is not doing its fair share and not fulfilling its full responsibility. We want to increase health transfers. We also want to provide the option for all Canadians to experience universal single-payer pharmacare.

Opposition Motion—PharmacareGovernment Orders

1 p.m.

Central Nova Nova Scotia

Liberal

Sean Fraser LiberalParliamentary Secretary to the Minister of Finance and to the Minister of Middle Class Prosperity and Associate Minister of Finance

Madam Speaker, I will be sharing my time with the member for Bonavista—Burin—Trinity.

Today's motion is about pharmacare. Perhaps I will lead with my conclusion. I will be supporting this motion. I will be supporting it because quite frankly I am sick of knocking on the doors of seniors who tell me they have to split their medication because they cannot afford it, not only putting themselves in a difficult financial position but reducing the effectiveness of the medicine they have been prescribed.

Most of the people I talk to at home, and I dare say most Canadians, are happy with their own coverage right now. However, the golden thread that runs through the social fabric of Canada is that as Canadians, we care as much about our neighbours as we do about ourselves. It is incredibly frustrating for me to know that one in five Canadian households report that a family member is not taking his or her medication because he or she cannot afford it. I am sure that the 36 million Canadians who do not suffer from this problem are disappointed to know that one million Canadians cut back on their food or home heating because they cannot afford the cost of their pills. When my neighbours cannot afford the cost of their medication, it decreases the quality of my life to know I live in a society that does not adequately take care of its vulnerable.

One of the greatest frustrations I have as a federal member of Parliament is that the number one issue for my constituents is their health care system, whether that is access to a family doctor, the quality of mental health services, in-home care for their aging parents or a lack of access to quality medications. They sometimes end up at my office, despite the fact that health care is primarily a provincial responsibility under our Constitution. It is cold comfort for the people who bring these kinds of concerns to my office for me to say that I have to wash my hands of it because it is a provincial responsibility. What they are looking for is help in often desperate circumstances.

Despite the fact that there is this constitutional division of power, there are concrete things the federal government can do, such as transfer more money to the provincial health care systems, invest in research, invest to ensure we can do something to combat the family doctor shortage, or, yes, implement a national pharmacare program to ensure people have access to the medications they have been prescribed so they can be healthy, regardless of the financial circumstances they may have been born into through no fault of their own.

There are two categories of problems I see with the lack of access to an adequate national pharmacare system.

First is the lack of access to medication because of issues surrounding affordability. I find this to be a real problem. It discriminates against our seniors on the basis of their age, because they do have increased health care concerns as they get older. It discriminates against people who are living in poverty, because they cannot afford to access drugs.

It is heartbreaking to knock on a door that is answered by a child who has not had enough to eat that day and then to sit down with his or her parents, who explain the child has been prescribed medication to which they do not have access. It also discriminates against people who have an underlying health condition that may not be the subject of coverage through private or public insurance plans. In fact, of the people who report they cannot afford their medication, 38% have access to a private insurance plan and 21% have access to public coverage that does not cover their needs.

Second, in addition to the lack of access is an issue around the lack of systemic savings that we are not benefiting from because we have not been moving forward.

The Parliamentary Secretary to the Minister of Health, a colleague of mine from Nova Scotia, quite eloquently has described the fact that Canada is the third most expensive country in the world when it comes to the costs of medication, ranking only behind the United States and Switzerland.

We are so proud of our public health care system and the universality of it. No matter where people come from or who their parents are, they will be taken care of when they fall ill. The same is not true, and a lot of Canadians do not appreciate this, when it comes to access to the medications they need, which are often to sustain life or remain healthy.

Part of the reason this is the case in Canada is that we have a very serious patchwork of provincial and territorial programs and over 100,000 private sector health care plans in Canada. We do not necessarily benefit from the opportunity that presents itself when we can negotiate bulk purchases of medications. Some efforts have yielded success by partnering with various provinces. However, if we adopt the Costco model and buy in greater volume, we can reduce the price per unit and extend access to people who currently cannot afford their medication.

I have seen estimates in excess of $4 billion of systemic savings that come not only from a reduced cost in the price of medication, but also fewer visits to emergency rooms, fewer hospitalizations and more seniors being taken care of in their homes because they can afford access to the medication they need to be well.

We all can appreciate that there is a problem with access to medication in Canada. Over the past few years we have been working toward solving this problem.

Just a few years ago, we appointed an advisory committee, led by Dr. Eric Hoskins, the former minister of health for the Province of Ontario. That effort led to a report that identified the path forward to a national pharmacare program. The committee flagged that it would not happen overnight, but there were certain things that needed to happen to bring down the cost of drugs so we could benefit from the systemic savings that would accrue once we implemented those steps.

One of the very first steps we thankfully moved forward with in the last federal budget, with a $35-million investment, was the creation of the Canada drug agency. This body would be able to assess the effectiveness of drugs that could be proposed to enter into the Canadian system. It would provide an opportunity to negotiate better prices because of the purchase of increased volume that could be administered through the provincial public health care systems. The creation of a national formulary would allow us to ensure we would have consistent coverage, regardless of which community of province in Canada one may live.

In addition to the creation of the Canada drug agency, we have created a national strategy for high-cost drugs and rare diseases. This is important. Quite a few Canadians live with a condition that, despite the fact they may have coverage, do not have access to the medication because of its exorbitant cost or their insurance policy may not provide coverage for their particular condition or its required medication. We have earmarked $500 million annually for this approach.

It is simply not fair that the circumstances of people's birth means they would not be entitled to benefit from the medication that could keep them alive. There are still problems in Canada. Tragic cases pop up in every corner of our country each week. However, by moving forward with this rare disease strategy, we will be able to help some of the most vulnerable Canadians.

In addition to the creation of a drug agency and rare disease strategy, we have also moved forward with changes to patented medicine regulations, changes that will save billions of dollars to our health care system. One of these changes adds additional factors that need to be considered so the cost of drugs reflect the benefits to public health care system in which they can enter. Some of the regulations will require better reporting to ensure our regulations reflect the actual cost of medication.

Perhaps most important, from my perspective, is we have changed the comparator basket of countries we look at to set drug prices for Canada by removing the United States and Switzerland, the two most expensive countries in the world, and added other comparator countries with similar economies, such as the Netherlands and Japan, which will lead to a systemic reduction in the cost of medication in our country and, most important, for Canadians who need that help.

Health care is front of mind for people back home, whether it is access to a family doctor, the fact that their parents cannot find a place in a long-term care facility or the underserved mental health services in their communities. I hear about these things non-stop because people recognize there are problems. Whether they live with those problems or not, they are equally concerned for the people who live in their communities who do not have access to life-saving services and, importantly, life-saving medication.

There is something we can do. We can implement a national pharmacare program to ensure that no matter where people live, no matter where they were born or their parents' economic situation, they will not be denied access to medication because of their financial circumstances.

It is Canada in the 21st century. Canadians expect that they and their neighbours will have access to the medications they need to be well. By implementing a national pharmacare program, we can turn that dream into a reality for the millions of Canadians who go without the medicines they so desperately need.

Opposition Motion—PharmacareGovernment Orders

1:10 p.m.

Bloc

Stéphane Bergeron Bloc Montarville, QC

Madam Speaker, I am very pleased to have the opportunity to put a question to the Parliamentary Secretary to the Minister of Finance, who I generally find to be very eloquent. I listened carefully to his speech, especially when he said that his greatest frustration as a federal MP was to see the difficulties experienced by our seniors and the most disadvantaged with health care.

I would like to ask him two questions. First, why did he not choose to run at the provincial level if his greatest concern is health care, which is not a federal jurisdiction but the exclusive jurisdiction of Quebec and the provinces?

Second, given that he chose to become a federal member and also the Parliamentary Secretary to the Minister of Finance, why not ensure that the federal government increases health transfers to make it possible for provinces to carry out their responsibilities and why does he not ensure the timely enactment of regulations lowering the cost of drugs?

Opposition Motion—PharmacareGovernment Orders

1:10 p.m.

Liberal

Sean Fraser Liberal Central Nova, NS

Madam Speaker, there is a lot to unpack in that question, but I will do my best to address it.

In addition to my frustrations with the shortcomings of the provincial health care system, there are other issues squarely within the federal purview that I care deeply about, notably the fight against climate change and solving income inequality in Canada, which in turn will actually have benefits for our provincial health care systems.

That being said, there are items within the federal purview that allow us to demonstrate leadership and assist the provinces in delivering the quality of care our citizens so desperately need.

In terms of the question regarding the increases to the quality of the financial transfers, I will note that we actually did land on a 10-year health accord that has seen the federal transfer go up. On top of that, we have created additional investments. My province of Nova Scotia has $288 million additional dollars for in-home care for seniors and to improve mental health services.

I would be happy to go over the role I see for the federal government to improve health care services with the hon. member at his leisure.

Opposition Motion—PharmacareGovernment Orders

1:15 p.m.

Green

Elizabeth May Green Saanich—Gulf Islands, BC

Madam Speaker, I am pleased to hear the parliamentary secretary's speech, but I would be more pleased if it were clear that Liberal members will be voting in favour of the opposition motion in the business of supply today. It is very clear that the majority of members of Parliament have been sent to this place by constituents who want a national pharmacare plan. Constituents want it to conform to the report by Dr. Hoskins, which was commissioned in the last Parliament. They do not want to risk delay. We want to get it passed while this minority Parliament is in session.

Could the hon. parliamentary secretary inform the House whether the Liberals will support this motion so we get a pharmacare plan in place as quickly as possible?

Opposition Motion—PharmacareGovernment Orders

1:15 p.m.

Liberal

Sean Fraser Liberal Central Nova, NS

Madam Speaker, to reiterate my opening comment, when I said I would lead with my conclusion, I will be supporting this motion. I speak not for the government, but for myself. I hope my colleagues will do the same.

The fact is that we have a time-limited opportunity in this minority Parliament to make a real difference that will extend access to medication to some of Canada's most vulnerable. I will never forgive myself if I do not take the opportunity to do everything within my power to ensure the most vulnerable Canadians have access to the medication they so desperately need.

Opposition Motion—PharmacareGovernment Orders

1:15 p.m.

Liberal

Brenda Shanahan Liberal Châteauguay—Lacolle, QC

Madam Speaker, I listened with interest and with emotion to what my colleague said he has been hearing from his constituents.

We, the members from the province of Quebec, already have a pharmacare plan, but my constituents have mentioned that there are gaps in coverage.

I would like my colleague to tell us what the federal government accomplished with this major process so we can create a pharmacare program that helps everyone.

Opposition Motion—PharmacareGovernment Orders

1:15 p.m.

Liberal

Sean Fraser Liberal Central Nova, NS

Madam Speaker, very quickly, we started by launching a nationwide consultation through the advisory council led by Dr. Hoskins. We followed that up with the creation of the Canada drug agency, which will ensure we can benefit from both purchasing and guarantee the effectiveness of drugs that enter the system.

Since then, we have made changes to certain medications to ensure we can bring the cost down and have some consistency in coverage. We have advanced a rare disease strategy, backed by hundreds of millions of dollars, to ensure the most vulnerable have access. These are the first steps in the process. We will get there and achieve universal coverage for drugs for Canadians.

Opposition Motion—PharmacareGovernment Orders

1:15 p.m.

Liberal

Churence Rogers Liberal Bonavista—Burin—Trinity, NL

Madam Speaker, it is a pleasure to rise today to discuss the motion tabled by the member for Vancouver Kingsway related to pharmacare. I too will be supporting this motion, because I believe and our government recognizes that the cost of drugs can directly affect the lives of Canadians.

Families should not have to choose between putting food on the table and paying for the drugs they need. That is why we have committed to implementing universal pharmacare to ensure that all Canadians have equitable and affordable access to the medicines they need.

Today I would like to highlight how the federal government is supporting innovative research to advance drug discovery and develop new therapies to improve the health of Canadians.

The Canadian Institutes of Health Research is the main federal agency responsible for funding health research across Canada. Every year the Government of Canada, through this group, invests over $1 billion in research initiatives that will generate new knowledge and evidence and lead to better and more affordable treatments for Canadians. Clinical trials are the cornerstone of an evidence-based practice and ensure timely access to new drugs and treatments for Canadians.

In 2016, CIHR launched the innovative clinical trials initiative. With an annual investment of $11.7 million, this initiative is supporting research focused on the development and implementation of innovative methods in clinical research. This specific initiative is part of the larger strategy for patient-oriented research, a national coalition of federal, provincial and territorial partners dedicated to the integration of research into care.

The SPOR innovative clinical trials initiative will contribute to increasing Canadian competitiveness in innovative clinical trials research and provide a stimulus for researchers to adopt new methodologies to conduct clinical trials. It will also encourage collaboration with various stakeholders, including patients, decision-makers and key stakeholders.

Innovative clinical trials use designs that are alternative to traditional trials methodologies. These new methods can reduce the cost of conducting trials, reduce the amount of time needed to answer research questions and increase the relevance of research findings to patients, health care providers and policy-makers. The direct outcome of these new methods is improved effectiveness of the trials while keeping the same high safety and effectiveness standards for the drugs. This will result in lowering the cost of drug development, ensuring that new, affordable and effective drugs are available for Canadians.

As part of this initiative, CIHR is supporting the CLEAN Meds project, led by researchers at Unity Health Toronto. Through a randomized controlled trial, researchers are investigating the effects of providing patients with free and convenient access to a selected set of medications. Each person is randomly assigned to either receive usual access to medications or to receive access to essential medications at no cost.

Preliminary findings from the CLEAN Meds trial demonstrate that the distribution of essential medicines at no charge for one year increased adherence to treatment medicines and improved some disease-specific health outcomes. These findings could help inform changes to medicine access policies such as publicly funding essential medicines.

Through the innovative clinical trials initiative, CIHR is also supporting a team led by Dr. Jacob Udell at the Women's College Hospital in Toronto. This work is looking at ways of leveraging big data to facilitate recruitment of patients in clinical trials, measurement of patient characteristics and follow-up of patient outcomes. It is expected that this approach will transform how clinical trials are conducted in Canada, which would ultimately contribute to lower drug development costs.

Leading researchers across the country are also conducting research to improve the safety and effectiveness of drugs. For example, CIHR is supporting a research project led by Dr. Michal Abrahamowicz at McGill University that aims to improve monitoring of adverse drug reactions. While most new drugs help improve patients' health, some may have important unintended side effects and others may be less effective than existing drugs. This research will allow for the development of new statistical methods that will allow for more accurate assessments of the safety and effectiveness of different drugs used by Canadians, and help to reduce the risk of serious adverse events.

Of course, underpinning all of this research are CIHR's research investments into the development of new drugs and therapies. For example, through CIHR's investigator-initiated programs, our government is investing $4.7 million in a research program led by Dr. Hanns Lochmüller at the Children's Hospital of Eastern Ontario Research Institute, right here in Ottawa, to discover and test several new therapies to treat neuromuscular diseases. Over 50,000 Canadians have a neuromuscular disease, of which there are over 150 types. Neuromuscular disease is associated with progressive muscle weakness, disability and early death, and can cause significant economic burdens on families that are affected.

Through his research, Dr. Lochmüller is using a combination of genomics, molecular biology, animal models and clinical trials to improve the diagnosis and treatment of neuromuscular disease. His objectives are to reveal the genetic mechanisms of 20 new genes associated with neuromuscular diseases, discover five new therapies and study seven therapies, four of which were repurposed and three new. The hope is that this research will lead to new ways to treat neuromuscular diseases.

Through the Canada research chairs program, CIHR is also supporting research led by Dr. Weihong Song at the University of British Columbia on Alzheimer's disease. Dementia has a significant and growing impact in Canada. We know that there are more than 419,000 Canadians aged 65 and older diagnosed with dementia. The impact of dementia on individuals, their families and the health care system is significant. In the absence of a cure or effective therapy, the total annual health care costs and out-of-pocket caregiver costs for Canadians with dementia are expected to exceed $16 billion by 2031. As the Canada Research Chair in Alzheimer's Disease, Dr. Song is studying the cause of dementia found in Alzheimer's disease and working to discover new drugs targeting Alzheimer's disease.

CIHR is also supporting groundbreaking research by Dr. Mick Bhatia at McMaster University in the hopes of uncovering new treatments for leukemia, a cancer that starts in blood stem cells.

Our government is committed to accelerating medical breakthroughs for people affected by rare diseases. Approximately one million people are affected by more than 7,000 different rare diseases in Canada. These diseases often appear at birth or emerge in early childhood. One-third of children with rare diseases die before their fifth birthday. For the vast majority of these conditions, there is no treatment available.

Canada, through CIHR and Genome Canada, is a founding member of the International Rare Diseases Research Consortium, which was established in April 2011 with a goal to develop 200 new therapies for rare diseases by 2020. I am pleased to note that the consortium had surpassed this target a few years early, with over 279 new medicinal products and therapies for rare diseases developed by 2017.

To conclude, I would like to reiterate that ensuring equitable access to necessary medicines is a priority for our government.